Appendix 4C
Quarter Ended 31 March 2018

San Diego, California and Sydney, Australia (Monday, 30 April 2018 - AEST) – REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company"), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2018. The Appendix 4C is unaudited.

First Quarter 2018 Highlights

During the first quarter of 2018, our first corporate priority continued to be the commercial success of our Fantom bioresorbable scaffold. The Company continued its efforts to rebuild the coronary bioresorbable scaffold market, which was impacted by the withdrawal of a key competitor in 2017. We expanded our commercial operations and invested in new product development and clinical evidence generation to grow commercial adoption of our technology. Physician awareness and interest in Fantom continues to increase, and we expect acceleration of new customer acquisition and product utilization throughout 2018.

Highlights from the quarter include:

- Expanding Commercial Operations – We doubled the size of our direct sales force with the addition of three new sales managers in Europe. Two sales managers joined on January 1, 2018 and one joined on February 1, 2018. We now have five sales managers and our Vice President, Europe driving commercial adoption of Fantom in Germany, Switzerland, and Austria. Our team is focused on new customer acquisition, customer training, and ensuring successful use of Fantom, which we expect will drive increased volume and reorder rates.

- New Product Development – We announced CE Mark and first implant of the 2.5 mm diameter size of Fantom Encore. Fantom Encore 2.5 mm has a market-leading 95 micron strut profile without compromising radial strength. Fantom Encore is made with Tyrocore, REVA's proprietary radiopaque bioresorbable polymer, making Fantom Encore the most advanced bioresorbable scaffold. We initiated launch at select centers while we pursue CE Mark for the 3.0 and 3.5 diameter sizes of Fantom Encore. We also submitted a CE Mark application for our radiopaque bioresorbable scaffold technology for use in below-the-knee revascularization.

- Clinical Data – We previously reported interim two-year results from our FANTOM II trial, which showed a low 5.6% rate of Major Adverse Cardiac Events in 125 patients. Two-year results on the full cohort of 240 patients will be presented on May 23, 2018 in a symposium at the EuroPCR Conference to be held in Paris, France at the Palais des Congres. In the first quarter of 2018, we continued enrolling patients in our FANTOM II Cohort C study in patients with long lesions and multi-vessel disease as well as our pilot study in patients with ST-segment elevated myocardial infarction. We also prepared for our 1,500-patient post market trial, which is expected to begin in May.

Total product shipments for the first quarter of 2018 were US $128,000, a 31% increase as compared to total product shipments for fourth quarter of 2017. Additionally, we saw a 78% increase in the number of customers ordering Fantom in the first quarter of 2018. Cash receipts from customers for the first quarter of 2018 were US $147,000, a 48% increase as compared to the fourth quarter of 2017.

Appendix 4C

As of 31 March 2018, the Company's cash, cash equivalents and investment securities balance was US $14.9 million; investment securities represent US $1,225,000. The Company's cash balance was US $13.6 million. The current quarter-end cash balance is a decrease of US $4.9 million from the 31 December 2017 balance of US $18.5 million reflecting US $5.3 million in disbursements related to normal operating activities, purchases of US $64,000 of capital equipment, offset by US $147,000 in receipts from customers and US $245,000 in maturities of investment securities.

The Company currently plans to file its Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission and with the Australian Securities Exchange on or before the due date of 10 May 2018. The Quarterly Report provides financial statements, along with Management's Discussion and Analysis of Financial Condition and Results of Operations for the quarter ended 31 March 2018.

About Fantom and Fantom Encore

Fantom and Fantom Encore are sirolimus-eluting bioresorbable scaffolds developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or "resorb") from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. Fantom and Fantom Encore are the only bioresorbable scaffolds made from Tyrocore, REVA's proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom and Fantom Encore the first and only bioresorbable scaffolds that are visible under fluoroscopy. Fantom and Fantom Encore are designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company's lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the

"SEC") on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003
Cheryl Liberatore
Director, Communications
+1 858-966-3045
ir@revamedical.com

Australia
Investor Enquiries:
Inteq Limited
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

REVA Medical, Inc.

ABN

ARBN 146 505 777

Quarter ended ("current quarter")

31 March 2018

Consolidated statement of cash flows		**Current quarter (Q1) $'000 USD**	**Year to date (3 months) $'000 USD**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	147	147
1.2	Payments for		
	(a) research and development	(895)	(895)
	(b) product manufacturing and operating costs	(468)	(468)
	(c) advertising and marketing	(119)	(119)
	(d) leased assets	—	—
	(e) staff costs	(3,024)	(3,024)
	(f) administration and corporate costs	(802)	(802)
1.3	Dividends received (see note 3)	—	—
1.4	Interest received	17	17
1.5	Interest and other costs of finance paid	—	—
1.6	Income taxes paid	—	—
1.7	Government grants and tax incentives	—	—
1.8	Other (provide details if material)	—	—
1.9	**Net cash from / (used in) operating activities**	**(5,144)**	**(5,144)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(64)	(64)
	(b) businesses (see item 10)	—	—
	(c) investments	—	—
	(d) intellectual property	—	—
	(e) other non-current assets	—	—

Consolidated statement of cash flows		**Current quarter (Q1) $'000 USD**	**Year to date (3 months) $'000 USD**
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	50	50
	(b) businesses (see item 10)	—	—
	(c) investments	245	245
	(d) intellectual property	—	—
	(e) other non-current assets	—	—
2.3	Cash flows from loans to other entities	—	—
2.4	Dividends received (see note 3)	—	—
2.5	Other (provide details if material)	—	—
2.6	**Net cash from / (used in) investing activities**	**231**	**231**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of shares	—	—
3.2	Proceeds from issue of convertible notes	—	—
3.3	Proceeds from exercise of share options	—	—
3.4	Transaction costs related to issues of shares, convertible notes or options	—	—
3.5	Proceeds from borrowings	—	—
3.6	Repayment of borrowings	—	—
3.7	Transaction costs related to loans and borrowings	—	—
3.8	Dividends paid	—	—
3.9	Other (repurchase of common stock)	—	—
3.10	**Net cash from / (used in) financing activities**	**—**	**—**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of quarter/year to date	18,544	18,544
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(5,144)	(5,144)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	231	231
4.4	Net cash from / (used in) financing activities (item 3.10 above)	—	—
4.5	Effect of movement in exchange rates on cash held	—	—
4.6	**Cash and cash equivalents at end of quarter**	**13,631**	**13,631**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $'000 USD**	**Previous quarter $'000 USD**
5.1	Bank balances	13,481	14,005
5.2	Call deposits	150	4,539
5.3	Bank overdrafts	—	—
5.4	Other (provide details)	—	—
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**13,631**	**18,855**

6.	**Payments to directors of the entity and their associates**	**Current quarter $'000 USD**
6.1	Aggregate amount of payments to these parties included in item 1.2	89
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	—

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Australian Director fees (1 non-executive directors)	USD $13
U.S. Director fees (6 non-executive directors)	USD $76

7.	**Payments to related entities of the entity and their associates**	**Current quarter $'000 USD**
7.1	Aggregate amount of payments to these parties included in item 1.2	—
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	—

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.	**Financing facilities available** *Add notes as necessary for an understanding of the position*	**Total facility amount at quarter end $'000 USD**	**Amount drawn at quarter end $'000 USD**
8.1	Loan facilities	—	—
8.2	Credit standby arrangements	—	—
8.3	Other (please specify)	—	—

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9.	**Estimated cash outflows for next quarter**	**$'000 USD**
9.1	Research and development	900
9.2	Product manufacturing and operating costs	500
9.3	Advertising and marketing	150
9.4	Leased assets	—
9.5	Staff costs	2,200
9.6	Administration and corporate costs	800
9.7	Other (costs of financing transaction)	—
9.7	Other (capital equipment)	—
9.8	**Total estimated cash outflows**	**4,550**

10.	**Acquisitions and disposals of business entities** (items 2.1(b) and 2.2(b) above)	**Acquisitions**	**Disposals**
10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Sign here: _____ */s/ Brandi L. Roberts* _____ Date: 30 April 2018
(Director/Company secretary)

Print name: Brandi L. Roberts

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.

2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.